EU IVDR Regulation 2017/746 Overview: Scope, Dates and Legal Basis

1. Key takeaways

The backbone legal instrument for in vitro diagnostic medical devices in the European Union is Regulation (EU) 2017/746, the IVDR. It was adopted on 5 April 2017, published in the Official Journal of the European Union as OJ L 117, 5.5.2017, p. 176, applies from 26 May 2022 and, from that date, replaces Directive 98/79/EC (IVDD). Because it is a Regulation rather than a Directive, it takes effect directly in the Member States and no longer depends on national transposition legislation.

Three points drive day-to-day compliance work. First, the entry-into-force date and the application date are not the same thing, and quoting them interchangeably creates errors in external documents. Second, Article 113(3) staggers the application of many obligations across several years, so a single project calendar is insufficient. Third, the IVDR and the MDR are sister regulations that share infrastructure but cannot be applied to each other by analogy, particularly on classification and evaluation.

2. Legal basis

The table below lists the primary sources that govern the application of the IVDR, as consolidated on EUR-Lex.

When citing these provisions in project files, reference the consolidated version on EUR-Lex that was current on the date of the assessment, and record that version number in the documentation. This practice keeps the evidence chain reproducible when later amendments, such as Regulation (EU) 2024/1860, change the wording of transitional provisions.

3. Expert insights

Insight 1: the difference between a Regulation and a Directive determines whether you can rely on national law alone.

The IVDD was a Directive, so its obligations reached manufacturers only after each Member State transposed it into domestic law; national variations were therefore structurally unavoidable. The IVDR is a Regulation, and its provisions bind economic operators directly. When building an EU IVD compliance file, the primary evidence chain should be anchored in the text of the Regulation itself, with national law consulted only for language requirements, fee schedules and enforcement details. Article 104 expressly permits Member States to charge fees on a transparent and cost-recovery basis, so fee levels remain a genuinely national matter and should be budgeted per country.

Insight 2: the application date and the entry-into-force date are not the same thing.

Article 113(1) provides that the Regulation enters into force on the twentieth day following publication. Official Commission materials record this as 26 May 2017, while materials issued by some other EU institutions record 25 May 2017; this is a difference in record-keeping convention and does not affect the application date. Article 113(2) makes clear that 26 May 2022 is the point from which obligations apply in full. Cite the two figures separately in regulatory documents, and never treat the entry-into-force date as the starting date for compliance obligations, because doing so shifts every derived deadline by a year and undermines the credibility of the timeline.

Insight 3: Article 113(3) is the master switch for staggered application.

Not every provision switched on together on 2022-05-26. Articles 31 to 46, governing notified bodies, apply since 26 November 2017, so the designation infrastructure predates the application date. Article 100, covering EU reference laboratories, applies since 25 November 2020. Under Article 24(4), UDI carriers apply in stages by class: 26 May 2023 for Class D, 26 May 2025 for Classes B and C, and 26 May 2027 for Class A. Finally, the common assessment procedure under Article 113(3)(g) applies from 26 May 2027. A project plan that assumes a single switch-on date will misstate at least four of these obligations.

Insight 4: the IVDR and the MDR are sister laws, but one cannot be mapped onto the other.

The MDR, Regulation (EU) 2017/745, was adopted on the same day as the IVDR, and the two share the EUDAMED database, the UDI system and the notified body framework. The IVDR nevertheless has its own seven classification rules, replaces clinical evaluation with performance evaluation, and adds EU reference laboratory verification and batch testing for Class D devices. Teams that transplant MDR experience directly onto IVD projects routinely underestimate the analytical evidence burden, and this mismatch is a leading source of certification delays and budget overruns.

4. Practical recommendations

1. At project initiation, build a legal-source inventory: number and layer the IVDR provisions, the applicable implementing regulations and the relevant MDCG guidance, and use that inventory as the citation base for all project documents.
2. Use 26 May 2022 as the dividing line between new devices and legacy devices, rather than judging by contract signature dates or shipment dates.
3. Structure the project timeline around three distinct categories of dates: the application date of the Regulation, the class-by-class UDI carrier dates, and the dates on which individual EUDAMED modules become mandatory.
4. Non-EU manufacturers should confirm in parallel the sequence between the EC REP requirement under Article 11 and the SRN requirement under Article 28, so that applications are not returned by the notified body on formal grounds.
5. Re-verify the consolidated text of the Regulation on EUR-Lex once every quarter, paying particular attention to whether Articles 110 and 113 have been amended by a new amending regulation.

5. Verification checklist

• □ Confirmed that the applicable legal source is Regulation (EU) 2017/746, not the repealed 98/79/EC
• □ Recorded the adoption date 2017-04-05, the OJ citation and the application date 2022-05-26
• □ Listed, under Article 113(3), the staggered provisions and dates relevant to the organisation’s products
• □ Distinguished the entry-into-force date from the application date and avoided mixing them in external documents
• □ Confirmed whether Article 110 legacy-device transition applies (if so, proceed to parts 05 and 06)
• □ Established a legal-source re-verification mechanism (recommended quarterly, as a practical estimate)

Regulatory information verified as of 29 October 2026.

GRZAN supports manufacturers, authorised representatives and importers entering or maintaining products on the European Union IVD market under Regulation (EU) 2017/746. Our team assists with IVD CE certification pathways, classification reviews, technical documentation, performance evaluation planning, notified body coordination and post-market surveillance setup, working from the regulatory framework summarised above. For tailored compliance support on the EU IVDR market, contact info@grzanglobal.com.